BioCentury
ARTICLE | Clinical News

Array gains on Phase III melanoma data

May 11, 2017 12:19 AM UTC

Array BioPharma Inc. (NASDAQ:ARRY) gained $1.41 (20%) to $8.43 on Wednesday after reporting that 45 mg binimetinib (MEK162) plus 300 mg encorafenib (LGX818) significantly improved median progression-free survival (PFS) over encorafenib monotherapy in Part 2 of the Phase III COLUMBUS trial to treat BRAF-mutant melanoma. The company said it is on track to submit an NDA for the combo in June or July. The data were announced after market close on Tuesday.

Last year, data from Part 1 of COLUMBUS showed that 45 mg binimetinib plus 450 mg encorafenib met the primary endpoint of improving median PFS over BRAF inhibitor Zelboraf vemurafenib, and narrowly missed a secondary endpoint of improving median PFS vs. 300 mg encorafenib alone (see BioCentury Extra, Sept. 26, 2016)...

BCIQ Company Profiles

Array BioPharma Inc.